

# BRAIN COMMUNICATIONS

## Molecular targets for endogenous glial cell line-derived neurotrophic factor modulation in striatal parvalbumin interneurons

Daniel Enterría-Morales,<sup>1,2</sup> Natalia López-González del Rey,<sup>3</sup>  Javier Blesa,<sup>3,4</sup> Ivette López-López,<sup>1</sup> Sarah Gallet,<sup>5</sup> Vincent Prévot,<sup>5</sup> José López-Barneo<sup>1,2,4</sup> and Xavier d'Anglemont de Tassigny<sup>1,2,4</sup>

Administration of recombinant glial cell line-derived neurotrophic factor into the putamen has been tested in preclinical and clinical studies to evaluate its neuroprotective effects on the progressive dopaminergic neuronal degeneration that characterizes Parkinson's disease. However, intracerebral glial cell line-derived neurotrophic factor infusion is a challenging therapeutic strategy, with numerous potential technical and medical limitations. Most of these limitations could be avoided if the production of endogenous glial cell line-derived neurotrophic factor could be increased. Glial cell line-derived neurotrophic factor is naturally produced in the striatum from where it exerts a trophic action on the nigrostriatal dopaminergic pathway. Most of striatal glial cell line-derived neurotrophic factor is synthesized by a subset of GABAergic interneurons characterized by the expression of parvalbumin. We sought to identify molecular targets specific to those neurons and which are putatively associated with glial cell line-derived neurotrophic factor synthesis. To this end, the transcriptomic differences between glial cell line-derived neurotrophic factor-positive parvalbumin neurons in the striatum and parvalbumin neurons located in the nearby cortex, which do not express glial cell line-derived neurotrophic factor, were analysed. Using mouse reporter models, we have defined the genomic signature of striatal parvalbumin interneurons obtained by fluorescence-activated cell sorting followed by microarray comparison. Short-listed genes were validated by additional histological and molecular analyses. These genes code for membrane receptors (*Kit*, *Gpr83*, *Tacr1*, *Tacr3*, *Mc3r*), cytosolic proteins (*Pde3a*, *Crabp1*, *Rarres2*, *Moxd1*) and a transcription factor (*Lhx8*). We also found the proto-oncogene *cKit* to be highly specific of parvalbumin interneurons in the non-human primate striatum, thus highlighting a conserved expression between species and suggesting that specific genes identified in mouse parvalbumin neurons could be putative targets in the human brain. Pharmacological stimulation of four G-protein-coupled receptors enriched in the striatal parvalbumin interneurons inhibited *Gdnf* expression presumably by decreasing cyclic adenosine monophosphate formation. Additional experiments with pharmacological modulators of adenylyl cyclase and protein kinase A indicated that this pathway is a relevant intracellular route to induce *Gdnf* gene activation. This preclinical study is an important step in the ongoing development of a specific pro-endo-glial cell line-derived neurotrophic factor pharmacological strategy to treat Parkinson's disease.

- 1 Instituto de Biomedicina de Sevilla (IBiS), Hospital Universitario Virgen del Rocío, CSIC, Universidad de Sevilla, Seville, Spain
- 2 Departamento de Fisiología Médica y Biofísica, Facultad de Medicina, Universidad de Sevilla, Seville, Spain
- 3 HM CINAC, Hospital Universitario HM Puerta del Sur, Móstoles, Spain
- 4 Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain
- 5 Univ. Lille, Inserm, CHU Lille, Lille Neuroscience & Cognition, Laboratory of Development and Plasticity of the Neuroendocrine Brain, UMR-S 1172, Lille, France

Correspondence to: Xavier d'Anglemont de Tassigny

Instituto de Biomedicina de Sevilla (IBiS)

Campus Hospital Universitario Virgen del Rocío, Avenida Manuel Siurot s/n, 41013 Seville, Spain

E-mail: xavier-ibis@us.es

Received April 12, 2020. Revised June 5, 2020. Accepted June 23, 2020. Advance Access publication July 15, 2020


© The Author(s) (2020). Published by Oxford University Press on behalf of the Guarantors of Brain.

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<http://creativecommons.org/licenses/by-nc/4.0/>), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact [journals.permissions@oup.com](mailto:journals.permissions@oup.com)

**Keywords:** Parkinson's disease; pro-endo-GDNF pharmacology; parvalbumin interneurons; striatum; gene expression

**Abbreviations:** AC = adenylyl cyclase; AMP = adenosine monophosphate; cAMP = cyclic adenosine monophosphate; CRABP1 = cellular retinoic acid-binding protein 1; CRE = cAMP response element; CREB = cAMP response element-binding protein; CTX = cortex; DA = dopamine; DE = differentially expressed; FACS = fluorescence-activated cell sorting; FC = fold-change; FSK = forskolin; GDNF = glial cell line-derived neurotrophic factor; GO = gene ontology; GPCR = G-protein-coupled receptor; GPR83 = G-protein-coupled receptor 83; LHX8 = LIM homeobox 8; MC3R = melanocortin receptor 3; NK1R = neurokinin receptor 1; NK3R = neurokinin receptor 3; PDE3A = phosphodiesterase 3A; PKA = protein kinase A; PV = parvalbumin; RA = retinoic acid; RARRES2 = retinoic acid receptor responder 2; RET = rearranged during transfection; SNpc = substantia nigra pars compacta; SPATA18 = spermatogenesis-associated 18; ST = striatum; XGal = 5-bromo-4-chloro-3-indolyl- $\beta$ -D-galactopyranoside.

## Graphical Abstract



## Introduction

Parkinson's disease, the second most prevalent neurodegenerative disorder, is characterized by the progressive loss of mid-brain dopamine (DA) neurons (Surmeier *et al.*, 2017). Currently, there are no therapies available to prevent damage to dopaminergic nigrostriatal neurons or promote regeneration of their axons, with existing treatments addressing symptom relief only (Pires *et al.*, 2017).

Glial cell line-derived neurotrophic factor (GDNF) has long been known for its potent trophic action on mesencephalic DA neurons (Lin *et al.*, 1993; Kordower and Bjorklund, 2013). GDNF binds to GDNF family receptor  $\alpha 1$  (GFR $\alpha 1$ ), and the resulting complex activates the RET receptor tyrosine kinase and subsequent downstream signals. Both receptors are expressed by DA neurons and their selective deletion in mice is associated with progressive loss of the nigrostriatal pathway (Kramer and Liss, 2015). Numerous preclinical studies involving rodent and non-human primate models have established the efficacy of cell-derived or recombinant GDNF treatment in protecting and restoring substantia nigra pars compacta (SNpc) DA neurons (Sauer *et al.*, 1995; Kirik *et al.*, 2004; Gash *et al.*, 2005; Muñoz-Manchado *et al.*, 2013). The clinical effect of GDNF treatment delivered directly

to the brain via intracerebral infusion devices has also been tested in Parkinson's disease patients (d'Anglemont de Tassigny *et al.*, 2015). Although safety has been shown for direct intraparenchymal injection of recombinant GDNF (Gill *et al.*, 2003) or viral-mediated strategy (Heiss *et al.*, 2019), clinical evidences have not fully demonstrated the efficacy of these approaches (Slevin *et al.*, 2005; Lang *et al.*, 2006). Recently, GDNF therapy in Parkinson's disease has regained attention due to the publication of a novel, intermittent intraputamenal delivery strategy to optimize GDNF diffusion (Whone *et al.*, 2019). Although the criteria for clinical improvement were not met after 40 weeks of GDNF delivery, this new approach resulted in significant progress on PET images. Indeed, there was a significant increase in  $^{18}\text{F}$ -DOPA putamenal uptake compared to the placebo group in patients that received GDNF (Whone *et al.*, 2019). These data, suggesting dopaminergic sprouting in the putamen, pointed to a regenerative effect of GDNF, an outcome that had previously been observed only in a single-case report (Love *et al.*, 2005).

The use of exogenous GDNF as restorative therapy for Parkinson's disease is faced with serious limitations (e.g. major surgery, outpatient care or intraputamenal delivery), which highlight the importance of the further

investigation to explore new options for GDNF-based neuroprotection. In this regard, new GDNF mimetic compounds, such as the brain penetrant RET receptor agonist BT13 (Mahato *et al.*, 2020), are also being tested with a good prospect. Interestingly, GDNF is naturally produced in the adult mammalian brain, particularly in the striatum (ST) (Springer *et al.*, 1994; Trupp *et al.*, 1997; Mogi *et al.*, 2001; Bäckman *et al.*, 2006) and provides trophic signals to distantly located somas of catecholaminergic neurons by retrograde transport along the axon (Ito and Enomoto, 2016). For instance, noradrenergic neurons of the locus coeruleus depend on GDNF expressed in the septo-thalamic regions (Arenas *et al.*, 1995; Zaman *et al.*, 2003; Pascual *et al.*, 2008; Enterría-Morales *et al.*, 2020). Likewise, GDNF produced in the ST seems to promote the survival of DA neurons located in the SNpc by stimulating their broad striatal axonal network. Although the physiological effects of striatal GDNF on DA nigrostriatal neurons are a matter of debate (Kopra *et al.*, 2015; Pascual and Lopez-Barneo, 2015; Enterría-Morales *et al.*, 2020), it is well established that heterozygous GDNF<sup>+/-</sup> mice show accelerated impairment of the nigrostriatal pathway and decline of motor coordination with age (Boger *et al.*, 2006). In addition, conditional deletion of the *Gdnf* gene in adult mice results in a progressive degeneration of the nigrostriatal dopaminergic pathway when GDNF levels are sufficiently low (Pascual *et al.*, 2008; Enterría-Morales *et al.*, 2020). Importantly, the main source of striatal GDNF has been identified as a subclass of GABAergic interneurons containing parvalbumin (PV), a calcium-binding protein (Hidalgo-Figueroa *et al.*, 2012). PV neurons are uniformly distributed throughout the ST, therefore providing a homogenous trophic support to the profusely ramified axons of nigrostriatal DA neurons. Genetically, modified PV neurons producing twice the normal amount of GDNF protect DA neurons from neurotoxic insults (Kumar *et al.*, 2015). Similarly, recent data obtained with SINEUPs, a new class of antisense long non-coding RNA targeting *Gdnf* mRNA, provided evidence that a 2-fold increase in GDNF is sufficient to significantly ameliorate motor deficits and prevent degeneration of DA neurons in a Parkinson's disease neurochemical mouse model (Espinoza *et al.*, 2020). These observations support the view that the pharmacological modulation of endogenous GDNF production in the ST, which is normally expressed at very low concentrations, could be a therapeutic approach to Parkinson's disease complementary to other treatments. Identifying molecular targets specific to striatal PV interneurons is therefore a critical step to stimulate GDNF production.

Here, we report the differential molecular characteristics of GDNF-synthesizing striatal PV interneurons and their potential role in endogenous GDNF modulation. We performed a detailed transcriptomic analysis of two PV interneuron populations with the same embryological origin (Marín *et al.*, 2000; Xu *et al.*, 2004) and sharing

several neurochemical and electrophysiological properties (Hu *et al.*, 2014) but differing in their ability to express GDNF [GDNF negative in the cortex (CTX) and GDNF positive in the ST] (this work). The specific striatal PV interneuron transcriptomic profile, obtained by using fluorescence-activated cell sorting (FACS) followed by microarray comparison, was validated by additional histological and molecular analyses, with some of the studies in mice extended to striatal PV interneurons in non-human primates. Finally, we evaluated the impact on GDNF synthesis of pharmacological modulation of PV interneuron membrane receptors and the cyclic adenosine monophosphate (cAMP)-protein kinase A (PKA) intracellular pathway.

## Materials and methods

### Mice

Adult heterozygous *Gdnf*<sup>flacZ</sup> mice were used for the detection of GDNF expression pattern (Sanchez *et al.*, 1996; Hidalgo-Figueroa *et al.*, 2012). The PV-*tdTomato* mice were obtained from The Jackson Laboratory (C57BL/6-*Tg(Pvalb-tdTomato)15Gfng/J* – JAX no. 027395), originally published in (Kaiser *et al.*, 2016). The PV-*Cre*; *tdTomato* mice were obtained by crossing PV-*Cre* mice (B6; 129P2-*Pvalb*<sup>tm1(cre)Arbr/J</sup> – JAX Stock no. 008069) (Hippenmeyer *et al.*, 2005) with *tdTomato* reporter mice (B6.Cg-*Gt(ROSA)26Sor*<sup>tm27.1(CAGCOP4\*H134R/tdTomato)Hze/J</sup> – JAX Stock no. 012567). All transgenic mice were bred in our animal facility and housed under a 12:12 h lighting schedule (lights on at 7:00 a.m.) with *ad libitum* access to food and water. The wild-type C57BL/6J mice for *ex vivo* experiments were purchased from Charles River France. Mice were sacrificed on postnatal Day 30 (P30) or at 2 months of age by thiobarbital overdose. All experiments were performed according to European Community guidelines (Council Directive 86/609/EEC) and were approved by the Ethics Committee of the 'Virgen de la Macarena' and 'Virgen del Rocío' hospitals (Seville, Spain) under project license no. 27-05-15-255 provided by the Government of Andalusia.

### Monkeys

We analysed brain tissue sections stored in our brain bank and obtained from control monkeys (*Macaca fascicularis*) used in previous publications (Blesa *et al.*, 2012; Jiménez-Sánchez *et al.*, 2020; Monje *et al.*, 2020). Non-human primate studies were performed according to European and Spanish guidelines (86/609/EEC and 2003/65/EC European Council Directives; and Spanish Government) and were approved by the research ethics committees of the universities of Navarra and Autónoma de Madrid.

## Histology and immunohistochemistry procedures

For histological detection of GDNF expression in adult mouse coronal brain sections, we revealed  $\beta$ -galactosidase activity with 5-bromo-4-chloro-3-indolyl- $\beta$ -D-galactopyranoside (XGal) staining. This step was followed by immunohistochemical detection of PV interneurons following the procedures detailed in the [Supplementary material](#). To reveal PV-Cre activity and PV-tdTomato fluorescence in the PV neurons, we followed the procedures detailed in the [Supplementary material](#) (see also [Enterria-Morales et al., 2020](#)). Co-expression analyses of cKit and PV in the mouse or monkey brain were performed as indicated in the [Supplementary material](#).

## Tissue dissociation and cell preparation

Motor and somatosensory CTX or dorsal ST brain regions were dissociated into single-cell suspensions using a protocol modified from [Zeisel et al. \(2015\)](#). See [Supplementary material](#) for extended protocol.

## Fluorescence-activated cell sorting

After dissociation of CTX and ST cells from *PV-Cre*; *tdTomato* or *PV-tdTomato* mice, tdTomato-positive cells were sorted using a FACS Jazz cell sorter (BD Biosciences). The tdTomato-positive cells were collected in *RNAlater* solution (Thermo Fisher Scientific) and immediately frozen at  $-80^{\circ}\text{C}$  until RNA isolation. The yield obtained from two *PV-Cre*; *tdTomato* brains was  $\sim 2000$  cells/CTX and  $\sim 250$ – $1000$  cells/ST. The yield from *PV-tdTomato* brains was  $\sim 5000$  cells/CTX and  $\sim 2000$  cells/ST. When necessary, cells from two or three sorting experiments were pooled to bring the total number to 2000 tdTomato-positive cells per replicate, which we estimated to be the minimum number required for microarray analysis ([Supplementary Fig. 1C and D](#)).

## CTX and ST whole tissue preparation

As described in the 'Tissue dissociation and cell preparation' section in [Supplementary material](#), mice were euthanized at P30 by thiobarbital overdose, and intracardially perfused with ice-cold oxygenated working solution (ICOWS). The brain was extracted rapidly, placed in  $\text{O}_2$ -saturated ICOWS, and sectioned (thickness  $300\mu\text{m}$ ) on a VT1200S vibratome (Leica). Next, brain slices were placed in oxygenated working solution at  $37^{\circ}\text{C}$  for 45 min and areas of interest (motor CTX; and dorsal ST) then dissected from each slice, snap frozen in liquid nitrogen, and stored at  $-80^{\circ}\text{C}$  until used for RNA isolation.

## RNA preparation, quality control and quantitation

Total RNA from cortical and striatal whole tissue samples and FACS-captured cells was isolated using the TRIzol method (Thermo Fisher) following the manufacturer's instructions with minor modifications. Quantification and quality control were performed using a Nanodrop 2000 spectrophotometer (Thermo Fisher) for tissue RNA, or with an Agilent 2100 Bioanalyzer system for RNA obtained from FACS-captured PV cells. See [Supplementary material](#) for detailed protocol.

## Microarray analysis

RNA from FACS-captured cells was amplified and labelled using Affymetrix GeneChip WT PLUS Reagent Kit (Thermo Fisher). Amplification was performed with 5 ng of total RNA as per procedures described in the WT PLUS Reagent Kit user manual. The amplified cDNA was quantified, fragmented and labelled in preparation for hybridization to an Affymetrix GeneChip Mouse Transcriptome 1.0 Array (Thermo Fisher) using  $5.5\mu\text{g}$  of single-stranded cDNA product and following protocols outlined in the user manual. Washing, staining (GeneChip Fluidics Station 450, Affymetrix) and scanning (GeneChip Scanner 3000, 10 Affymetrix) were performed as per protocols outlined in the user manual for cartridge arrays. Data were processed for gene-level background subtraction, normalization and signal summarization (SST-RMA, signal space transformation-robust multi-array average) using the BioConductor oligo package (R version 3.2.3) ([Carvalho and Irizarry, 2010](#)). To assess the overall similarity among samples, hierarchical clustering analysis of full expression profiles and principal component analysis were then performed. For hierarchical clustering analysis, the Pearson correlation metric and complete agglomeration methods were used. Differential expression analysis was performed using the R Limma (Linear Models for Microarray Analysis) package. This analysis applies a *t*-test empirically adjusted by a Bayes test ([Huber et al., 2015](#)). Changes in gene expression between groups were considered significant with false discovery rate (FDR)  $< 0.05$  and fold change  $> 2$  or  $< -2$ . Heatmap figures (hierarchical clustering) were obtained using the Transcriptome Analysis Console 3.0 Software (TAC 3.0) from Affymetrix.

## Real-time quantitative RT-PCR

Real-time quantitative RT-PCR (qPCR) was run to validate the microarray results obtained from the FACS-captured PV-positive cells, as well as to compare transcriptomic differences between the PV cells and whole tissue from which they were isolated. See [Supplementary Table 1](#) and [Supplementary material](#) for the full protocol.

## RNAscope

We carried out *in situ* hybridization using the protocol from Advanced Cell Diagnostics (ACDbio), following the manufacturer's instructions (RNAscope® Fluorescent Multiplex kit). This technique is used to visualize single RNA molecules in tissue samples on glass slides (Wang *et al.*, 2012). See [Supplementary material](#) for extended protocol and analysis.

## Ex vivo pharmacological experiments

We used 250 µm-thick coronal slices containing the ST (hemibrain) prepared from P30 male mice. The slices were kept in oxygenated artificial cerebrospinal fluid (aCSF) at 36°C and challenged with different pharmacological compounds for 5 or 12 h. At the end of incubation, striatal regions were dissected from each slice of the same hemibrain, placed in *RNAlater* and stored at –80°C until RNA extraction. Survival tests consisting of amperometric measurements of DA release in response to high potassium were performed to validate this *ex vivo* protocol. See [Supplementary material](#) for detailed procedures and pharmacological compounds used in this study.

## In vivo stereotaxic experiments

Detailed procedures for administering stereotaxic injections into 2-month-old f male mice are available in the [Supplementary material](#).

## Statistical analysis

No statistical methods were used to predetermine sample size. For qPCR analyses, a minimum of two technical replicates were performed, with mean values used in calculations. Statistical analysis was performed using Prism software version 6.0 (GraphPad). Normality was tested with the Shapiro–Wilk test. We applied ordinary one-way analysis of variance with Tukey's multiple comparison tests for a parametric set of data, or one-way ANOVA on ranks (Kruskal–Wallis) for non-parametric tests. A two-tailed Student's *t*-test was performed for pairwise data. Data were presented as the mean ± SEM with the number (N) of experiments indicated in the figures. A value of  $P < 0.05$  was considered statistically significant. Significance thresholds are indicated with asterisks in the figures as  $P < 0.05$ ,  $P < 0.01$ ,  $P < 0.001$  and  $P < 0.0001$ , and standard errors of the mean are indicated by error bars. The statistical analysis specific to the microarray data is described in the 'Microarray analysis' section.

## Data availability

The gene expression datasets generated in this study are available through NCBI Gene Expression Omnibus

(GEO) with the series accession number (GEO: GSE100300). All other data generated or analysed during this study are included in this published article (and [Supplementary material](#) files).

## Results


### Differential GDNF expression in PV interneuron populations

We studied neural GDNF expression by histological XGal staining of coronal brain sections from adult *Gdnf<sup>lacZ</sup>* mice, which showed  $\beta$ -galactosidase activity resulting from the *LacZ* insert within exons 1 and 2 of the *Gdnf* gene. Dual XGal and PV immunohistochemical staining showed that, as reported previously (Hidalgo-Figueroa *et al.*, 2012), GDNF is expressed in more than 95% of striatal PV-positive interneurons distributed uniformly over the ST (Fig. 1A and B). Remarkably, XGal staining, indicative of GDNF expression, was never seen in the PV neurons of the nearby somatosensory CTX or external globus pallidus (Fig. 1B). Moreover, the qPCR analysis confirmed the XGal data, as *Gdnf* mRNA expression levels were much higher in the ST than in the CTX of the mouse brain ( $P < 0.01$ ,  $N = 4$ ) (Fig. 1C). Indeed, *Gdnf* mRNA was barely amplified in cortical tissue. These data indicate that GDNF is selectively expressed by the striatal subclass of brain PV interneurons.

### Reporter mouse models and PV cell sorting

To capture PV-positive cells by FACS, we bred two mouse models expressing the red fluorescent protein variant tdTomato (Fig. 2A and [Supplementary Fig. 1](#)). We first used Cre-inducible tdTomato mice (*PV-Cre; tdTomato*), which harbour a loxP-flanked STOP cassette preventing the transcription of a CAG promoter-driven channelrhodopsin-2 (ChR2)/tdTomato fusion protein. Following exposure to Cre recombinase, the ChR2/tdTomato fusion protein is expressed with a predominant membrane location ([Supplementary Fig. 2A](#)). Only about half of PV interneurons are tdTomato-positive in the ST and CTX of this model due to a relatively low Cre-mediated recombination (Enterria-Morales *et al.*, 2020). This resulted in few FACS-captured cells (see below) and, therefore, several sorting experiments were pooled to reach the critical threshold of 2000 cells required to guarantee good-quality RNA ([Supplementary Fig. 1C and D](#)).

The second mouse strain studied (transgenic *PV-tdTomato*) was free of Cre recombinase and constitutively expressed tdTomato in PV interneurons. Soluble tdTomato fluorescence was easily detected in 30 µm-thick brain cross-sections (Fig. 2A). Consistent with the original characterization of this model (Kaiser *et al.*, 2016), we observed that most PV-immunopositive cells were



**Figure 1 Selective expression of GDNF in mouse striatal PV interneurons.** (A) Schematic illustration of the CTX, ST and globus pallidus in a coronal section of the mouse brain. (B) Immunostaining of PV interneurons (brown) and selective expression of GDNF, reported by positive XGal-positive staining (blue dots), in the ST. (a), (b) and (c) are magnified fields showing details such as XGal blue dots only visible in (b). (C) Comparison of *Gdnf* mRNA expression (measured by qPCR) in the ST and CTX ( $N = 4$ , \*\*  $P < 0.01$ , two-tailed Student's t-test).


tdTomato-positive in CTX and striatal regions (Supplementary Fig. 2B).

We set up a FACS protocol to specifically capture PV interneurons from striatal and cortical tissue preparations (Fig. 2B and C). In each model, dispersed cells from tdTomato-negative mice were used to detect non-specific fluorescence and to set up the gate to collect selectively tdTomato-positive cells. In a typical experiment, brain tissues were pooled from two *PV-Cre; tdTomato* mice and 1000–4000 (CTX) and 250–1000 (ST) tdTomato-positive cells were harvested, accounting for ~3% and ~0.5% of the total cell number, respectively. A typical harvest from two *PV-tdTomato* brains was 4000–10 000 cells from the CTX and 1000–2500 cells from the ST, representing ~2.5% and ~1% of the total cell number, respectively. Figure 2B shows representative FACS plots from *PV; tdTomato* striatal tissue; additional FACS plots for the two mouse models used are presented in Supplementary


Fig. 3. To illustrate FACS selectivity, cells collected from the positive gate were red fluorescent under 568 nm excitation wavelength, whereas cells harvested from the negative gate were non-fluorescent (Fig. 2D). PV neuron enrichment was also confirmed by qPCR. *Pvalb* expression was high in captured tdTomato-positive cells from both the ST and CTX compared to cells harvested from the negative gate. In addition, only striatal tdTomato-positive cells exhibited high *Gdnf* mRNA levels (Fig. 2E). ST- and CTX-derived tdTomato-positive cells were then processed for RNA isolation and microarray analysis (Fig. 2F).

### Transcriptomic differences between ST- and CTX-derived PV interneurons

The expression profiles of 24 334 genes of FACS-captured PV neurons were compared between CTX and ST



**Figure 2 Experimental workflow for cell sorting from PV-tdTomato mice and microarray analysis.** (A) Left, gene construction of PV-tdTomato mice and schematic illustration of CTX (CTX) and ST tissue samples obtained for cell dispersion. Right, histological examples of fluorescent cells (tdTomato-positive) in CTX and ST. (B) Flow cytometry dot plot graphical analysis of dispersed cells from tdTomato-negative (+/+) or positive (tdTomato+/+) ST. The sorting gate (red line) was defined to separate the tdTomato-positive cells (pos) from other cells (see Supplementary Fig. 3 for extended plots). A negative gate was set to collect tdTomato-negative cells (white square). (C) 2000 tdTomato-positive cells (pos) were collected for experiment. (D) Phase contrast and fluorescence (568 nm filter) composite microphotographs of floating FACS-captured striatal cells. Left, negative gate-captured cells. Right, positive gate-captured cells. (E) Qualitative comparison of *Gdnf* and *Pvalb* mRNA expression (measured by qPCR) in tdTomato-positive and negative cells obtained from cortical and striatal cell preparations (*N* = 1). (F) Schematic diagram illustrating the experimental workflow after FACS capture of tdTomato-positive cells. Cells were processed for RNA extraction followed by quality check. Samples with an RNA integrity number above 7 were selected for the Affymetrix microarray procedure. Final data were analysed by bioinformatics to compare gene expression between ST and CTX parvalbumin interneurons.



in two separate microarray experiments (corresponding to *PV-Cre; tdTomato* and *PV-tdTomato* mouse models). As illustrated by volcano plots (Fig. 3A and B), a number of differentially expressed (DE) genes between ST- and CTX-derived PV neurons were distributed in the top left ( $FDR < 0.05$  and  $\log_2 FC < -1$ ) and top right ( $FDR < 0.05$  and  $\log_2 FC > 1$ ) sections of the plots. In the *PV-Cre; tdTomato* model, 294 DE genes were identified (Fig. 3A and Supplementary Table 2). In contrast, 199 DE genes were identified in PV cells from *PV-tdTomato* mice (Fig. 3B and Supplementary Table 3). Two model-combined differential expression analyses ( $FDR < 0.05$ ,

$\log_2 FC > 1$  or  $< -1$ ) yielded 185 DE genes specific to *PV-Cre; tdTomato* mice, and 90 DE genes specific to the *PV-tdTomato*-derived PV neurons. Finally, 109 DE genes overlapped in the two models (Fig. 3C). Although *Gdnf* was not DE in the initial microarray analysis, FDR and P-value indicate enrichment in striatal PV cells (Fig. 3D). Clustering of selected ST-specific DE genes showed that genes such as *Gpr83*, *Mia*, *Tmem212*, *Spata18*, *Mc4r*, *Pde3a* and *Prokr2* are shared between the two reporter models (Fig. 3E and F). Other DE genes, such as *Kit*, were identified in *PV-Cre; tdTomato* mice but not in *PV-tdTomato* mice (Fig. 3E). On the other hand, *Mc3r*,

*Tacr1*, *Tacr3* and *Lhx8* were DE only in striatal PV cells of PV-*tdTomato* mice (Fig. 3F).


We next short-listed several DE genes obtained from the two models to carry out qPCR validation. This short-list was based on positive ST/CTX fold change (i.e. higher expression in striatal PV interneurons) and biological interest (membrane receptors, cellular function and gene regulation). For this step, we included cDNA prepared from whole tissue samples (ST or CTX) in order to discard DE genes that although showed regional specificity was not highly expressed in PV neurons. Figure 4 shows qPCR data from eleven striatal PV-enriched genes (*Kit*, *Gpr83*, *Mc3r*, *Tacr1*, *Tacr3*, *Crabp1*, *Rarres2*, *Moxd1*, *Pde3a*, *Spata18* and *Lhx8*). Other DE genes were discarded because exhibited either a low level of expression in PV neurons or high, non-PV-neuron-selective regional differences (ST versus CTX) (Supplementary Fig. 4). These genes were considered marginally selective and, therefore, less relevant for our study.

## Histological analysis of PV interneuron-specific gene expression



Based on microarray and qPCR data, we examined the anatomical distribution of selected PV neuron-specific genes in the mouse brain with particular attention paid to

the ST. We first browsed through the Allen Mouse Brain Atlas *in situ* hybridization database for pattern similarity (Lein *et al.*, 2007) and found a very similar distribution across the ST between *Pvalb* and some of our short-listed striatal PV neuron-specific genes (*Crabp1*, *Lhx8*, *Pde3a*, *Tacr1*, *Tacr3*) (Supplementary Fig. 5). We next searched for co-expression of selected genes in the mouse brain by histological methods. We chose the *Kit* gene for immuno-histochemical analysis as highly specific antibodies for the cKit receptor are available (May *et al.*, 2018) and determined that virtually all PV-immunopositive neurons were also cKit-positive in the mouse ST. On the other hand, only a small proportion of striatal cKit-positive cells were PV-negative (Fig. 5A; Supplementary Fig. 6A). Although cKit-positive cells were observed in the nearby somatosensory CTX, very few expressed both cKit and PV (Supplementary Fig. 6B). These histological results confirm the molecular data regarding *Kit* gene expression. In the absence of highly specific antibodies, we performed RNAscope® *in situ* hybridization analyses to examine *Gpr83* and *Lhx8* expression in the ST. *Gpr83*, *Lhx8* and *Gdnf* mRNA were clearly co-labelled in the ST as illustrated in Fig. 5B (and Supplementary Fig. 7). These histological results support the molecular data described above.

To evaluate whether the PV neuron-specific genes identified in the mouse ST might be conserved across species, we



**Figure 4 Differential gene expression between parvalbumin interneurons from ST and CTX compared to tissue gene expression level in P30 mice.** (A) Schematic illustration of parvalbumin interneurons (in red) within the whole CTX or ST region (yellow) in a coronal section of the mouse brain. Vertical bar graphs show cDNA level (measured by qPCR), as a measure of mRNA, in FACS-captured PV interneurons (red) and in whole tissue preparation (yellow) from ST (ST) and CTX (CTX). Gene expression for each sample was normalized to *Actb* mRNA. (B) Genes coding for membrane receptors. (C) Genes coding for cell signalling- and metabolism-associated proteins. (D) Gene coding for the transcription factor LHX8. *N* = 3 or 4, \**P* < 0.05, \*\**P* < 0.01, non-parametric one-way ANOVA on ranks (Kruskal–Wallis test).

**A Immunohistochemistry****B RNAscope**

**Figure 5 Selective expression of cKit (protein), Gpr83 and Lhx8 (mRNA) in Gdnf-positive mouse striatal parvalbumin interneurons.** (A) Left, histological immunodetection of parvalbumin (PV, magenta) and cKit receptor (green) in coronal brain sections. Right, quantification of striatal PV-positive interneurons expressing cKit (circle plot on left), and cKit-positive cells expressing PV (circle plot on right) with co-expression percentages indicated (N = 3 adult mice). (B) *In situ* hybridization (by RNAscope method) analysis of *Gdnf*, *Gpr83* and *Lhx8* gene expression in the mouse ST. Greyscale confocal microphotographs show, from left to right: nuclei (stained by DAPI), specific probes for *Gdnf*, *Gpr83* and *Lhx8* mRNA. High magnification pictures of the fields delineated by dotted lines are displayed below the respective lower magnification images. Bottom left corner of the panel, composite image with merged labelling for *Gdnf*, *Gpr83* and *Lhx8*. The circle plots indicate quantification of striatal *Gdnf*-positive cells expressing *Gpr83* mRNA (left circle plot), *Lhx8* mRNA (centre circle plot, and both *Gpr83* and *Lhx8* mRNAs (right circle plot) with co-expression percentages indicated (N = 3 adult mice). Additionally,  $36 \pm 4\%$  of the *Gpr83*-positive cells were positive for *Gdnf* mRNA, and  $86 \pm 3\%$  of *Lhx8*-positive cells expressed *Gdnf* mRNA in the ST (data not shown).

investigated the expression of cKit in the *Macaca fascicularis*, brain, a non-human primate model studied previously in our laboratories (Blesa et al., 2012; Jiménez-Sánchez et al., 2020;


Monje et al., 2020). We stained the striatal PV-positive interneuron population and showed their resilience to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine treatment

(Supplementary Fig. 8). This observation in monkey brain supported our previous data obtained in the mouse brain showing that *Gdnf*-expressing striatal PV interneurons survive to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine -induced DA depletion (Hidalgo-Figueroa *et al.*, 2012). Dual labelling of the caudate nucleus and putamen showed a tight and selective co-expression of PV and cKit. Over 99% of PV-positive neurons appeared cKit-positive in the caudate nucleus and putamen of the *Macaca fascicularis* brain (Fig. 6). As previously observed in mice, cKit and PV were predominantly expressed by distinct cells in the nearby cortical region (only 4.4% of PV-positive neurons were cKit-positive). These

results in the monkey are thus comparable to those obtained in the mouse brain.

### GDNF modulation by pharmacological activation of PV interneuron-specific G-protein-coupled receptors

To assess whether stimulation of striatal PV interneuron-specific G-protein-coupled receptors (GPCRs) modulates GDNF expression, we tested *ex vivo* the effect of specific



**Figure 6 Selective expression of cKit in striatal parvalbumin interneurons of non-human primate brain.** (A) Immunostaining of parvalbumin (PV) interneurons (green) and cKit receptor (magenta) in the putamen (top) and CTX (bottom) of the *Macaca fascicularis* brain. Insets show magnified images of fields demarcated by dotted lines. (B) Quantification analysis of PV-positive and cKit-positive co-labelling is presented as circle plots. Upper row, PV-positive cells expressing cKit in caudate (N = 3), putamen (N = 3) and CTX (N = 4). Lower row, cKit-positive cells expressing PV in caudate, putamen and CTX. Note the co-expression of PV and cKit in the putamen. In the CTX, PV-positive and cKit-positive cells are distinct neurons.

agonists of GPR83, MC3R, NK1R (from *Tacr1*) and NK3R (from *Tacr3*). First, we showed that *ex vivo* slices remained viable after up to 12 h of incubation; this was done by measuring the striatal external  $\text{Ca}^{2+}$ -dependent DA release in response to depolarization with high potassium (40 mM KCl) using an amperometric carbon-fibre electrode (Supplementary Fig. 9) (Mejías et al., 2006). The GPR83-specific agonist mPEN (Gomes et al., 2016) significantly reduced the level of *Gdnf* mRNA in the ST after 5 h of incubation (Fig. 7A). Likewise, incubation with the MC3R agonist Melanotan II significantly decreased *Gdnf* mRNA content after a long-lasting (12 h) incubation (Fig. 7B). Finally, stimulation of the tachykinin receptor NK3R, by 5  $\mu\text{M}$  and 10  $\mu\text{M}$  Senktide, proved to significantly inhibit *Gdnf* gene expression (Fig. 7C). However, stimulation of the neurokinin B receptor NK1R by its specific agonist GR73632 showed no statistically significant effect (Fig. 7C). In parallel to the actions on *Gdnf* modulation, we analysed the effects of the GPCR agonists on *Fos* gene expression, a proto-oncogene used as a marker of neuronal activity (Morgan et al., 1987; Didier et al., 2018), to rule out a non-selective pan-neuronal action of the agonists. The lack of changes in *Fos* expression (Fig. 7A–C) suggested that GPR83, MC3R and NK3R agonists act selectively on striatal PV interneurons to down-regulate *Gdnf* expression.

### Pro-endo-GDNF effect of cyclic-AMP/PKA pathway stimulation


Gene ontology analysis performed on cells from PV-CRE; *tdTomato* and PV-*tdTomato* mice suggested the up-regulation of several signalling pathways in PV-positive neurons (see Supplementary Tables 4 and 5). Interestingly, gene ontology analysis of ST versus CTX gene DE from PV-*tdTomato* mice revealed a positive perturbation of the adenylyl cyclase (AC)/cyclic adenosine 3',5'-monophosphate (cAMP) signalling pathway (Supplementary Table 5). Based on these data, we carried out *ex vivo* experiments to test the effect of pharmacological modulation of this pathway on *Gdnf* gene expression. We assayed the effect of dibutyryl-cAMP (dbcAMP), a cell-permeable cAMP analogue that activates cAMP-dependent protein kinases (PKA), and observed that incubation for 5 h with 1 mM dbcAMP was the optimal condition to obtain a consistent increase in striatal *Gdnf* mRNA levels (Fig. 8A and Supplementary Fig. 10). Similar results were obtained with direct activation of AC by forskolin (FSK, 50  $\mu\text{M}$ ) (Fig. 8B). The increase in *Gdnf* gene expression induced by dbcAMP or FSK was partially prevented by 666-15 (10  $\mu\text{M}$ ), a selective cAMP response element-binding protein (CREB) inhibitor (Fig. 8C and D). The effect of 666-15 was confirmed based on the expression of *Ptgs2*, a well-known CREB-sensitive gene coding for prostaglandin-endoperoxide synthase 2 (Xie et al., 2015)

(Supplementary Fig. 11). *Gdnf* mRNA expression was also modulated by incubation of slices with cadmium chloride (200  $\mu\text{M}$ ), a blocker of voltage-gated  $\text{Ca}^{2+}$  channels (Ureña et al., 1994), suggesting that  $\text{Ca}^{2+}$  entry contributes to striatal GDNF homeostasis (Fig. 8E and F). In parallel with *ex vivo* experiments, we tested the effects of the intrastriatal administration of dbcAMP and FSK in anaesthetized mice. While dbcAMP had no effect on *Gdnf* mRNA levels (Fig. 8G), FSK evoked a significant 1.5-fold increase in *Gdnf* gene expression (Fig. 8H). As expected, generalized activation of the AC-cAMP-PKA pathway also induced the expression of *Fos* (Supplementary Fig. 10).

## Discussion

The intrastriatal administration of GDNF is a potential disease-modifying therapeutic strategy for Parkinson's disease that has been intensely studied in preclinical models as well as in patients though with variable results in the latter (Gill et al., 2003; Lang et al., 2006; Slevin et al., 2007). Recently, the design of a new protocol for GDNF delivery has raised hopes concerning its clinical efficacy (Whone et al., 2019). GDNF is produced in the mammalian brain, and adult central catecholaminergic neurons seem to rely on endogenous GDNF production for survival (Arenas et al., 1995; Pascual et al., 2008; Enterria-Morales et al., 2020). The main source of striatal GDNF in adult mice are GABAergic PV interneurons, which are densely innervated by nigrostriatal dopaminergic nerve endings that capture the GDNF necessary for the trophic maintenance of SNpc neurons (see Hidalgo-Figueroa et al., 2012 and references therein). Based on these early findings, the main goal of this work was to define a signature gene expression profile in striatal GABAergic PV interneurons, which could help to identify molecular targets for the pharmacological modulation of endogenous GDNF production.

A fundamental observation in our study was that, whereas more than 95% of mouse striatal PV neurons express GDNF, this property is completely absent in the neighbouring and more numerous neocortical (and globus pallidus) PV interneurons, despite the fact that all three neuronal classes share a similar embryological origin (Marin et al., 2000; Xu et al., 2004) and functional properties (Hu et al., 2014). This finding, which further suggests a neuroprotective role of striatal GDNF on mesencephalic dopaminergic neurons, also provides an optimal experimental model for separation of GDNF-producing (ST) and non-GDNF-producing (CTX) PV neuronal populations, thereby facilitating the study of their differential molecular properties. To this end, we performed a comparative transcriptomic analysis of *tdTomato*-labelled striatal versus cortical GABAergic PV cells using cDNA microarrays with posterior qPCR validation in two different transgenic mouse models. A point worth clarifying is that our analysis focused on the entire population of




**Figure 7 Effect on *Gdnf* gene expression of pharmacological modulation of GPCRs expressed in striatal parvalbumin interneurons.** Vertical bar graphs indicate *Gdnf* mRNA level (measured by qPCR with *Hmbs* gene as internal reference) in the ST from brain slices incubated for 5 or 12 h under ex vivo conditions. The level of *Fos* mRNA was used as a marker for pan-neuronal activation (measured by qPCR and normalized to *Actb* mRNA). (A) Stimulation of GPR83 by selective mPEN (1 μM) for 5 h. (B) Stimulation of Melanocortin receptor 3 (MC3R) by Melanotan II (20 μM) for 5 or 12 h. (C) Stimulation of tachykinin receptors 1 and 3 (NK1R, NK3R) for 5 h by their respective specific agonists GR73632 (GR73; 10 μM) and Senktide (10 μM). The number of experimental replicates (N) is indicated above the bar graphs. \*  $P < 0.05$ , \*\*  $P < 0.01$ , two-tailed Student's t-test for two sample differences, or one-way ANOVA with Tukey's multiple comparison test were applied.

striatal PV interneurons, because all them express GDNF, although specific subclasses of PV striatal interneurons have been described based on their intrinsic electrical properties (Garas *et al.*, 2016; Monteiro *et al.*, 2018), functional inputs (Klug *et al.*, 2018) or single-cell RNA

sequencing (Muñoz-Manchado *et al.*, 2018). Indeed, some of the PV genes reported in this last-mentioned study are coincident with the gene profile described here.

Within the several DE genes found in striatal versus cortical PV neurons, we defined 11 genes coding for



**Figure 8** Effect of modulation of the cyclic-AMP/protein kinase and calcium-dependent pathways on striatal *Gdnf* gene expression under *ex vivo* and *in vivo* conditions. Vertical bar graphs indicate *Gdnf* mRNA level (measured by qPCR with *Hmbs* or *Actb* genes as internal reference) in the ST after 5 h incubation under *ex vivo* conditions, or 4 h after stereotaxic intrastriatal administration (*in vivo*). (A) *Ex vivo* stimulation of PKA by dibutyl-AMP (dbcAMP; 1 mM) versus control (CTL). (B) *Ex vivo* stimulation of AC by FSK (50μM) versus control (DMSO vehicle) (C) *Ex vivo* stimulation of PKA by dbcAMP (1 mM) and effect of 666-15 (10 μM), a selective CREB inhibitor: (D) *Ex vivo* stimulation of AC by FSK 50μM and effect of 10 μM of 666-15. (E) *Ex vivo* stimulation of PKA by dbcAMP (1 mM) and effect of CdCl<sub>2</sub> (200 μM), a blocker of voltage-gated calcium channel. (F) *Ex vivo* stimulation of AC by FSK (50μM) and effect of CdCl<sub>2</sub> (200 μM). (G) *In vivo* stimulation of PKA with intrastriatal administration of 49 μg dbcAMP, with controls receiving PBS. (H) *In vivo* stimulation of AC with intrastriatal administration of 8.2 μg FSK, with controls receiving DMSO. The number of experimental replicates (N) is indicated above the bar graphs. \*  $P < 0.05$ , \*\*  $P < 0.01$ , \*\*\*  $P < 0.001$ , \*\*\*\*  $P < 0.0001$ , two-tailed Student's *t*-test or one-way ANOVA with Tukey's multiple comparison test.

potentially relevant proteins, such as membrane receptors or cell signalling and transcription factors, with high striatal PV interneuron specificity. Some differences observed in the highly expressed genes between the two reporter mouse models could be ascribed to a non-specific effect of Cre recombinase present only in the *PV-Cre*; *tdTomato* strain (Harno et al., 2013) or to a bias introduced by the distinct localization of the fluorescent signal (anchored to the plasma membrane in *PV-Cre*; *tdTomato* or free in the cytosol in *PV-tdTomato*) influencing the

cell sorting output. However, these possibilities were ruled out given the selectivity of specific genes that was confirmed by immunocytochemistry and RNAscope in wild-type mice. The proto-oncogene *Kit*, which encodes a tyrosine kinase receptor, was found to be highly expressed in striatal PV interneurons in the *PV-Cre*; *tdTomato* model only. However, detailed immunohistochemical analyses in normal mice showed that this membrane-spanning receptor is actually expressed in almost 100% of striatal PV interneurons, both in mice and

monkeys, and that this close association is not seen in other brain regions. In the same way, striatal *Lhx8* mRNA expression, which is only seen in PV-*tdTomato* mice, was confirmed to be a robust property of *Gdnf*-positive PV interneurons of the adult normal mouse ST that is also regionally conserved in humans (Hawrylycz *et al.*, 2012). LHX8 is a transcription factor broadly expressed in the developing mouse brain that functions as a cell fate regulator to median ganglionic eminence-derived cells (Zhao *et al.*, 2003), which include cholinergic projection neurons and PV interneurons (Mayer *et al.*, 2018). Embryonic deletion of the *Lhx8* gene causes loss of the nucleus basalis of Meynert and a dramatic drop in the number of striatal cholinergic neurons, although PV interneurons remain present in adult *Lhx8*-null mice (Zhao *et al.*, 2003).

Among the striatal PV signature genes, five code for GPCRs (GPR83, MC3R, NK1R and NK3R) and a phosphodiesterase (PDE3A), suggesting the participation of the cAMP/PKA/CREB pathway in GDNF expression. This is supported by the existence of a least three cAMP-responsive elements (CREs) in the GDNF promoter (Lamberti and Vicini, 2014) and the stimulatory effect of follicle-stimulating hormone, which acts on G<sub>s</sub>-coupled receptors, on GDNF production by Sertoli cells (Reichert and Dattatreyaumurthy, 1989; Parekh *et al.*, 2019). Indeed, we showed that direct pharmacological activation of AC or dbcAMP induced clear increases in striatal GDNF mRNA levels which were inhibited by the blockade of CREB. In contrast, stimulation of three of the four specific agonists of the GPCRs found in the PV interneurons (GPR83, MC3R and NK3R) resulted in a significant inhibition of *Gdnf* gene expression. It has been shown that GPR83 receptors signal via G<sub>i</sub> (Mack *et al.*, 2019) and that their activation with PEN (a physiological ligand) leads to a dose-dependent decrease in intracellular cAMP (Gomes *et al.*, 2016). Therefore, it is possible that the endogenous activation of MC3R and NK3R receptors also decreases intracellular cAMP. In this manner, local neuropeptides of the tachykinin family, such as substance P, which is known to be released by striatal neurons (He *et al.*, 2019), could provide basal inhibition of the cAMP/PKA/CREB pathway in PV cells that contributes to maintaining a low physiological production of GDNF.

Along with GPCRs, our study also suggests that the retinoic acid (RA) signalling pathway could also contribute to low basal striatal GDNF production because two RA-related genes (*Crabp1* and *Rarres2*) appeared in the signature profile of PV neurons. CRABP1 (cellular retinoic acid-binding protein 1) is a cytoplasmic RA carrier that promotes the activation of specific RA nuclear receptors to eventually regulate the transcription of different sets of genes. However, CRABP1 is also a signalling molecule that mediates numerous rapid, non-genomic actions of RA, such as dampening growth factor sensitivity in stem cells, prevention of over-activation of calcium-calmodulin-dependent protein kinase II in heart cells, or

modulation of the Raf-Ras-MEK-ERK signalling pathway (Nagpal and Wei, 2019; Park *et al.*, 2019). Regarding the genomic actions of RA, a recent study on Sertoli cells showed that RA negatively regulates GDNF synthesis through binding of RAR $\alpha$  to a new RA response element, DR5-RARE, on the *Gdnf* promoter (Saracino *et al.*, 2020). Moreover, in some cell lines, RA induces transcriptional upregulation of retinoic acid receptor responder 2 (RARRES2), a poorly known protein that seems to act as a chemokine, adipokine or growth factor and has been associated with metabolic disorders (Helfer and Wu, 2018). However, it has been shown that RARRES2 promotes  $\beta$ -catenin phosphorylation and degradation (Liu-Chittenden *et al.*, 2017). The interaction of RARRES2 with the Wnt/ $\beta$ -catenin canonical pathway could be of particular interest for understanding striatal GDNF modulation, as it is known that inhibition of glycogen synthetase kinase 3 prevents  $\beta$ -catenin degradation and leads to strong induction of GDNF in Sertoli cells (Tanwar *et al.*, 2010). Interestingly, the Wnt/ $\beta$ -catenin pathway is required for embryonic differentiation and survival of mesencephalic dopaminergic neurons (Castelo-Branco *et al.*, 2004; Joksimovic and Awatramani, 2014) and its dysregulation has been implicated in Parkinson's disease pathogenesis (Zhang *et al.*, 2016; Berwick *et al.*, 2017). GDNF induction by  $\beta$ -catenin may also explain the functional role of *Kit* and *Lhx8* genes that, as indicated above, are highly specific to striatal PV cells. It has been shown that cKit can directly phosphorylate tyrosine residues in  $\beta$ -catenin and increase its translocation to the nucleus and transcriptional activity (Kajiguchi *et al.*, 2008; Jin *et al.*, 2014). On the other hand, the *Lhx8* promoter contains an enhancer with an evolutionarily conserved binding site for  $\beta$ -catenin (Landin Malt *et al.*, 2014); transgenic LIM homeobox protein 8 (LHX8) over-expression increases  $\beta$ -catenin levels and its nuclear translocation (Zhou *et al.*, 2015). Moreover, *Lhx8*<sup>-/-</sup> mice show a drastic down-regulation of *Kit* in neonatal ovaries (Choi *et al.*, 2008). Therefore, it seems that LHX8 could induce cKit and activate the  $\beta$ -catenin pathway to further upregulate *Lhx8* expression.

The last two specific striatal PV genes to discuss here are *Spata18* and *Moxd1*. *Spata18* codes for spermatogenesis-associated 18 homologue protein which is expressed in embryonic and adult testis (Bornstein *et al.*, 2011). While the function of SPATA18 is poorly understood, it appears to be involved in the degradation of unhealthy mitochondria (Kitamura *et al.*, 2011). *Moxd1*, which codes for DA beta hydroxylase-like monooxygenase protein, could contribute to the local inactivation of neurotransmitter in striatal dopaminergic synapses, although this function has not been demonstrated.

Taken together, our findings suggest that striatal GDNF homeostasis depends on a complex and delicate equilibrium between several signalling pathways. Strong inhibition of the cAMP/PKA/CREB pathway and the activation of RA signalling are probably responsible for a

low basal level of GDNF synthesis and secretion by PV neurons. GDNF homeostasis is likely more complex and involves regulation at several non-transcriptomic levels (d'Anglemont de Tassigny *et al.*, 2015). For instance, *Gdnf* mRNA degradation is highly regulated by microRNAs (Kumar *et al.*, 2015; Xia *et al.*, 2016; Zhang *et al.*, 2019). However, a low basal level of expression is probably necessary to prevent over-activation of dopaminergic terminals and deleterious effects of GDNF. It is well known that local injection of GDNF produces structural aberrations in SNpc neurons (Kirik *et al.*, 2000a, b); and that the intracerebroventricular injection of GDNF in humans induces a wide variety of side effects (Nutt *et al.*, 2003). Overlapping with this tonic inhibition, selective activation of the cKit and Wnt/ $\beta$ -catenin pathways could result in a controlled production of GDNF as per physiological needs. In sum, the therapeutic potential of PV interneurons as a target is significant since they are the only cells to synthesize GDNF in the ST. These neurons remain functional, and continue producing GDNF after experimental destruction of nigrostriatal dopaminergic neurons in mice (Hidalgo-Figueroa *et al.*, 2012) and monkeys (this work). We have shown that striatal GDNF production can be pharmacologically modulated (increased or decreased) and have also identified several pathways with druggable targets that are potentially relevant for controlling GDNF synthesis and/or release by striatal PV neurons. Development of a specific and safe pharmacology capable of modulating striatal GDNF production in man is a feasible goal that could eventually be of major therapeutic benefit for combating Parkinson's disease.

## Supplementary material

Supplementary material is available at *Brain Communications* online.

## Acknowledgements

The authors wish to thank Dr. Patricia Ortega-Saenz for her help with the amperometric measurements, and Dr. Francisco Morón-Civanto, Mr. Juan Cordero-Varela and Ms. Maria José Castro-Pérez for their technical assistance. We also thank the IBiS animal facility staff for excellent animal care.

## Funding

This research was supported by the Spanish Ministries of Science and Innovation and Health (SAF2012-39343, SAF2016-74990-R), the Carlos III Health Institute's Miguel Servet Program (CPII17/00016, CP19/00200), the European Research Council (ERC-ADGPRJ201502629), the

Fundación BBVA (Ayudas a Equipos de Investigación Científica 2015) and the Agence Nationale de la Recherche grants ANR-17-CE16-0015 and the LabEx DistAlz.

## Competing interests

The authors report no competing interests. An international patent was submitted with registration number PCT/ES2018/070577 (authors: J.L.-B., X.D.T., D.E.-M. and I.L.-L.).

## References

- Arenas E, Trupp M, Akerud P, Ibáñez CF. GDNF prevents degeneration and promotes the phenotype of brain noradrenergic neurons in vivo. *Neuron* 1995; 15: 1465–73.
- Bäckman CM, Shan L, Zhang YJ, Hoffer BJ, Leonard S, Troncoso JC, et al. Gene expression patterns for GDNF and its receptors in the human putamen affected by Parkinson's disease: a real-time PCR study. *Mol Cell Endocrinol* 2006; 252: 160–6.
- Berwick DC, Javaheri B, Wetzel A, Hopkinson M, Nixon-Abell J, Grannò S, et al. Pathogenic LRRK2 variants are gain-of-function mutations that enhance LRRK2-mediated repression of  $\beta$ -catenin signaling. *Mol Neurodegener* 2017; 12: 9.
- Blesa J, Pifl C, Sanchez-Gonzalez MA, Juri C, Garcia-Cabezas MA, Adanez R, et al. The nigrostriatal system in the presymptomatic and symptomatic stages in the MPTP monkey model: a PET, histological and biochemical study. *Neurobiol Dis* 2012; 48: 79–91.
- Boger H, Middaugh L, Huang P, Zaman V, Smith A, Hoffer B, et al. A partial GDNF depletion leads to earlier age-related deterioration of motor function and tyrosine hydroxylase expression in the substantia nigra. *Exp Neurol* 2006; 202: 336–47.
- Bornstein C, Brosh R, Molchadsky A, Madar S, Kogan-Sakin I, Goldstein I, et al. SPATA18, a spermatogenesis-associated gene, is a novel transcriptional target of p53 and p63. *Mol Cell Biol* 2011; 31: 1679–89.
- Carvalho BS, Irizarry RA. A framework for oligonucleotide microarray preprocessing. *Bioinformatics* 2010; 26: 2363–7.
- Castelo-Branco G, Rawal N, Arenas E. GSK-3 $\beta$  inhibition/ $\beta$ -catenin stabilization in ventral midbrain precursors increases differentiation into dopamine neurons. *J Cell Sci* 2004; 117: 5731–7.
- Choi Y, Ballow DJ, Xin Y, Rajkovic A. Lim homeobox gene, *lhx8*, is essential for mouse oocyte differentiation and survival. *Biol Reprod* 2008; 79: 442–9.
- d'Anglemont de Tassigny X, Pascual A, López-Barneo J. GDNF-based therapies, GDNF-producing interneurons, and trophic support of the dopaminergic nigrostriatal pathway. Implications for Parkinson's disease. *Front Neuroanat* 2015; 9: 1–15.
- Didier S, Sauve F, Domise M, Buee L, Marinangeli C, Vingtdeux V. AMP-activated protein kinase controls immediate early genes expression following synaptic activation through the PKA/CREB pathway. *Int J Mol Sci* 2018; 19: 3716.
- Enterria-Morales D, López-López I, López-Barneo J, d'Anglemont de Tassigny X. Role of glial cell line-derived neurotrophic factor in the maintenance of adult mesencephalic catecholaminergic neurons. *Mov Disord* 2020; 1–12.
- Espinoza S, Scarpato M, Damiani D, Managò F, Mereu M, Contestabile A, et al. SINEUP non-coding RNA targeting GDNF rescues motor deficits and neurodegeneration in a mouse model of Parkinson's disease. *Mol Ther* 2020; 28: 642–52.
- Garas FN, Shah RS, Kormann E, Doig NM, Vinciati F, Nakamura KC, et al. Secretagogin expression delineates functionally-specialized populations of striatal parvalbumin-containing interneurons. *Elife* 2016; 5: e16088.

- Gash DM, Zhang Z, Ai Y, Grondin R, Coffey R, Gerhardt G. A. Trophic factor distribution predicts functional recovery in parkinsonian monkeys. *Ann Neurol* 2005; 58: 224–33.
- Gill SS, Patel NK, Hotton GR, O'Sullivan K, McCarter R, Bunnage M, et al. Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease. *Nat Med* 2003; 9: 589–95.
- Gomes I, Bobeck EN, Margolis EB, Gupta A, Sierra S, Fakira AK, et al. Identification of GPR83 as the receptor for the neuroendocrine peptide PEN. *Sci Signal* 2016; 9: 1–15.
- Harno E, Cottrell EC, White A. Metabolic pitfalls of CNS Cre-based technology. *Cell Metab* 2013; 18: 21–8.
- Hawrylycz MJ, Lein ES, Guillozet-Bongaarts AL, Shen EH, Ng L, Miller JA, et al. An anatomically comprehensive atlas of the adult human brain transcriptome. *Nature* 2012; 489: 391–9.
- He Z, Liu TY, Yin YY, Song HF, Zhu XJ. Substance P plays a critical role in synaptic transmission in striatal neurons. *Biochem Biophys Res Commun* 2019; 511: 369–73.
- Heiss JD, Lungu C, Hammoud DA, Herscovitch P, Ehrlich DJ, Argersinger DP, et al. Trial of magnetic resonance-guided putaminal gene therapy for advanced Parkinson's disease. *Mov Disord* 2019; 34: 1073–8.
- Helfer G, Wu QF. Chemerin: a multifaceted adipokine involved in metabolic disorders. *J Endocrinol* 2018; 238: R79–R94.
- Hidalgo-Figueroa M, Bonilla S, Gutiérrez F, Pascual A, López-Barneo J. GDNF is predominantly expressed in the PV+ neostriatal interneuronal ensemble in normal mouse and after injury of the nigrostriatal pathway. *J Neurosci* 2012; 32: 864–72.
- Hippenmeyer S, Vrieseling E, Sigrist M, Portmann T, Laengle C, Ladle DR, et al. A developmental switch in the response of DRG neurons to ETS transcription factor signaling. *PLoS Biol* 2005; 3: e159.
- Hu H, Gan J, Jonas P. *Interneurons. Fast-spiking, parvalbumin(+) GABAergic interneurons: from cellular design to microcircuit function.* *Science* 2014; 345: 1255263.
- Huber W, Carey VJ, Gentleman R, Anders S, Carlson M, Carvalho BS, et al. Orchestrating high-throughput genomic analysis with Bioconductor. *Nat Methods* 2015; 12: 115–121.
- Ito K, Enomoto H. Retrograde transport of neurotrophic factor signaling: implications in neuronal development and pathogenesis. *J Biochem* 2016; 160: 77–85.
- Jiménez-Sánchez L, Blesa J, Del Rey NL, Monje MHG, Obeso JA, Cavada C. Serotonergic innervation of the striatum in a nonhuman primate model of Parkinson's disease. *Neuropharmacology* 2020; 170: 107806.
- Jin B, Ding K, Pan J. Ponatinib induces apoptosis in imatinib-resistant human mast cells by dephosphorylating mutant D816V KIT and silencing  $\beta$ -catenin signaling. *Mol Cancer Ther* 2014; 13: 1217–30.
- Joksimovic M, Awatramani R. Wnt/ $\beta$ -catenin signaling in midbrain dopaminergic neuron specification and neurogenesis. *J Mol Cell Biol* 2014; 6: 27–33.
- Kaiser T, Ting JT, Monteiro P, Feng G. Transgenic labeling of parvalbumin-expressing neurons with tdTomato. *Neuroscience* 2016; 321: 236–45.
- Kajiguchi T, Lee S, Lee M-J, Trepel JB, Neckers L. KIT regulates tyrosine phosphorylation and nuclear localization of beta-catenin in mast cell leukemia. *Leuk Res* 2008; 32: 761–70.
- Kirik D, Rosenblad C, Björklund A, Mandel RJ. Long-term rAAV-mediated gene transfer of GDNF in the rat Parkinson's model: intrastriatal but not intranigral transduction promotes functional regeneration in the lesioned nigrostriatal system. *J Neurosci* 2000a; 20: 4686–700.
- Kirik D, Rosenblad C, Björklund A. Preservation of a functional nigrostriatal dopamine pathway by GDNF in the intrastriatal 6-OHDA lesion model depends on the site of administration of the trophic factor. *Eur J Neurosci* 2000b; 12: 3871–82.
- Kirik D, Georgievska B, Björklund A. Localized striatal delivery of GDNF as a treatment for Parkinson disease. *Nat Neurosci* 2004; 7: 105–10.
- Kitamura N, Nakamura Y, Miyamoto Y, Miyamoto T, Kabu K, Yoshida M, et al. Micap, a p53-inducible protein, controls mitochondrial quality by repairing or eliminating unhealthy mitochondria. *PLoS One* 2011; 6: e16060.
- Klug JR, Engelhardt MD, Cadman CN, Li H, Smith JB, Ayala S, et al. Differential inputs to striatal cholinergic and parvalbumin interneurons imply functional distinctions. *Elife* 2018; 7: e35657.
- Kopra J, Vilenius C, Grealish S, Härma M, Varendi K, Lindholm J, et al. GDNF is not required for catecholaminergic neuron survival in vivo. *Nat Neurosci* 2015; 18: 319–322.
- Kordower JH, Björklund A. Trophic factor gene therapy for Parkinson's disease. *Mov Disord* 2013; 28: 96–109.
- Kramer ER, Liss B. GDNF – ret signaling in midbrain dopaminergic neurons and its implication for Parkinson disease. *FEBS Lett* 2015; 589: 3760–3772.
- Kumar A, Kopra J, Varendi K, Porokukka LL, Panhelainen A, Kuure S, et al. GDNF overexpression from the native locus reveals its role in the nigrostriatal dopaminergic system function. *PLOS Genet* 2015; 11: e1005710.
- Lamberti D, Vicini E. Promoter analysis of the gene encoding GDNF in murine Sertoli cells. *Mol Cell Endocrinol* 2014; 394: 105–14.
- Landin Malt A, Cesario JM, Tang Z, Brown S, Jeong J. Identification of a face enhancer reveals direct regulation of LIM homeobox 8 (LHX8) by wingless-int (WNT)/beta-catenin signaling. *J Biol Chem* 2014; 289: 30289–30301.
- Lang AE, Gill S, Patel NK, Lozano A, Nutt JG, Penn R, et al. Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease. *Ann Neurol* 2006; 59: 459–66.
- Lein ES, Hawrylycz MJ, Ao N, Ayres M, Bensinger A, Bernard A, et al. Genome-wide atlas of gene expression in the adult mouse brain. *Nature* 2007; 445: 168–176.
- Lin HF, Doherty DH, Lile JD, Bektesh S, Collins F. GDNF: a glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons. *Science* 1993; 260: 1130–1132.
- Liu-Chittenden Y, Jain M, Gaskins K, Wang S, Merino MJ, Kotian S, et al. RARRES2 functions as a tumor suppressor by promoting  $\beta$ -catenin phosphorylation/degradation and inhibiting p38 phosphorylation in adrenocortical carcinoma. *Oncogene* 2017; 36: 3541–52.
- Love S, Plaha P, Patel N, Hotton G, Brooks D, Gill S. Glial cell line-derived neurotrophic factor induces neuronal sprouting in human brain. *Nat Med* 2005; 11: 703–704.
- Mack SM, Gomes I, Devi LA. Neuropeptide PEN and its receptor GPR83: distribution, signaling, and regulation. *ACS Chem Neurosci* 2019; 10: 1884–1891.
- Mahato AK, Kopra J, Renko J-M, Visnapuu T, Korhonen I, Pulkkinen N, et al. Glial cell line-derived neurotrophic factor receptor rearranged during transfection agonist supports dopamine neurons in vitro and enhances dopamine release in vivo. *Mov Disord* 2020; 35: 245–255.
- Marin O, Anderson SA, Rubenstein JL. Origin and molecular specification of striatal interneurons. *J Neurosci* 2000; 20: 6063–76.
- May AJ, Cruz-Pacheco N, Emmerson E, Gaylord EA, Seidel K, Nathan S, et al. Diverse progenitor cells preserve salivary gland ductal architecture after radiation-induced damage. *Development* 2018; 145: dev166363.
- Mayer C, Hafemeister C, Bandler RC, Machold R, Batista Brito R, Jaglin X, et al. Developmental diversification of cortical inhibitory interneurons. *Nature* 2018; 555: 457–462.
- Mejias R, Villadiego J, Pintado CO, Vime PJ, Gao L, Toledo-Aral JJ, et al. Neuroprotection by transgenic expression of glucose-6-phosphate dehydrogenase in dopaminergic nigrostriatal neurons of mice. *J Neurosci* 2006; 26: 4500–4508.
- Mogi M, Togari A, Kondo T, Mizuno Y, Kogure O, Kuno S, et al. Glial cell line-derived neurotrophic factor in the substantia nigra from control and parkinsonian brains. *Neurosci Lett* 2001; 300: 179–81.

- Monje MHG, Blesa J, García-Cabezas MÁ, Obeso JA, Cavadia C. Changes in thalamic dopamine innervation in a progressive Parkinson's disease model in monkeys. *Mov Disord* 2020; 35: 419–30.
- Monteiro P, Barak B, Zhou Y, Mcrae R, Rodrigues D, Wickersham IR, et al. Dichotomous parvalbumin interneuron populations in dorsolateral and dorsomedial striatum. *J Physiol* 2018; 596: 3695–707.
- Morgan JL, Cohen DR, Hempstead JL, Curran T. Mapping patterns of c-fos expression in the central nervous system after seizure. *Science* 1987; 237: 192–197.
- Muñoz-Manchado AB, Bengtsson Gonzales C, Zeisel A, Munguba H, Bekkouche B, Skene NG, et al. Diversity of Interneurons in the Dorsal Striatum Revealed by Single-Cell RNA Sequencing and PatchSeq. *Cell Rep* 2018; 24: 2179–90.e7.
- Muñoz-Manchado AB, Villadiego J, Suárez-Luna N, Bermejo-Navas A, Garrido-Gil P, Labandeira-García JL, et al. Neuroprotective and reparative effects of carotid body grafts in a chronic MPTP model of Parkinson's disease. *Neurobiol Aging* 2013; 34: 902–15.
- Nagpal I, Wei L-N. All-trans retinoic acid as a versatile cytosolic signal modulator mediated by CRABP1. *Int J Mol Sci* 2019; 20: 3610.
- Nutt JG, Burchiel KJ, Comella CL, Jankovic J, Lang AE, Laws ER, et al. Randomized, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PD. *Neurology* 2003; 60: 69–73.
- Parekh PA, Garcia TX, Hofmann M-C. Regulation of GDNF expression in Sertoli cells. *Reproduction* 2019; 157: R95–R107.
- Park SW, Nhieu J, Persaud SD, Miller MC, Xia Y, Lin Y-W, et al. A new regulatory mechanism for Raf kinase activation, retinoic acid-bound Crabp1. *Sci Rep* 2019; 9: 10929.
- Pascual A, Hidalgo-Figueroa M, Piruat JI, Pintado CO, Gómez-Díaz R, López-Barneo J. Absolute requirement of GDNF for adult catecholaminergic neuron survival. *Nat Neurosci* 2008; 11: 755–61.
- Pascual A, Lopez-Barneo J. Reply to GDNF is not required for catecholaminergic neuron survival in vivo. *Nat Neurosci* 2015; 18: 322–323.
- Pires AO, Teixeira FG, Mendes-Pinheiro B, Serra SC, Sousa N, Salgado AJ. Old and new challenges in Parkinson's disease therapeutics. *Prog Neurobiol* 2017; 156: 69–89.
- Reichert LE, Dattatreya Murthy B. The follicle-stimulating hormone (FSH) receptor in testis: interaction with FSH, mechanism of signal transduction, and properties of the purified receptor. *Biol Reprod* 1989; 40: 13–26.
- Sanchez M, Silos-Santiago I, Frisen J, He B, Lira S, Barbacid M. Renal agenesis and the absence of enteric neurons in mice lacking GDNF. *Nature* 1996; 382: 70–73.
- Saracino R, Capponi C, Di S, Carla P, Masciarelli S, Fazi F, et al. Regulation of GDNF expression by retinoic acid in Sertoli cells. *Mol Reprod Dev* 2020; 87: 419–11.
- Sauer H, Rosenblad C, Bjorklund A. Glial cell line-derived neurotrophic factor but not transforming growth factor beta 3 prevents delayed degeneration of nigral dopaminergic neurons following striatal 6-hydroxydopamine lesion. *Proc Natl Acad Sci USA* 1995; 92: 8935–8939.
- Slevin JT, Gash DM, Smith CD, Gerhardt GA, Kryscio R, Chebrolu H, et al. Unilateral intraputamenal glial cell line-derived neurotrophic factor in patients with Parkinson disease: response to 1 year of treatment and 1 year of withdrawal. *J Neurosurg* 2007; 106: 614–20.
- Slevin JT, Gerhardt G. A, Smith CD, Gash DM, Kryscio R, Young B. Improvement of bilateral motor functions in patients with Parkinson disease through the unilateral intraputamenal infusion of glial cell line-derived neurotrophic factor. *J Neurosurg* 2005; 102: 216–22.
- Springer J, Mu X, Bergmann L, Trojanowski J. Expression of GDNF mRNA in rat and human nervous tissue. *Exp Neurol* 1994; 127: 167–170.
- Surmeier JD, Obeso JA, Halliday GM. Selective neuronal vulnerability in Parkinson disease. *Nat Rev Neurosci* 2017; 18: 101–113.
- Tanwar PS, Kaneko-Tarui T, Zhang L, Rani P, Taketo MM, Teixeira J. Constitutive WNT/beta-catenin signaling in murine Sertoli cells disrupts their differentiation and ability to support spermatogenesis. *Biol Reprod* 2010; 82: 422–32.
- Trupp M, Belluardo N, Funakoshi H, Ibáñez CF. Complementary and overlapping expression of glial cell line-derived neurotrophic factor (GDNF), c-ret proto-oncogene, and GDNF receptor-alpha indicates multiple mechanisms of trophic actions in the adult rat CNS. *J Neurosci* 1997; 17: 3554–3567.
- Ureña J, Fernández-Chacón R, Benot AR, Alvarez De Toledo G, López-Barneo J. Hypoxia induces voltage-dependent Ca<sup>2+</sup> entry and quantal dopamine secretion in carotid body glomus cells. *Proc Natl Acad Sci USA* 1994; 91: 10208–10211.
- Wang F, Flanagan J, Su N, Wang LC, Bui S, Nielson A, et al. RNAscope: a novel in situ RNA analysis platform for formalin-fixed, paraffin-embedded tissues. *J Mol Diag* 2012; 14: 22–29.
- Whone A, Luz M, Boca M, Woolley M, Mooney L, Dharia S, et al. Randomized trial of intermittent intraputamenal glial cell line-derived neurotrophic factor in Parkinson's disease. *Brain* 2019; 142: 512–525.
- Xia Z-Q, Ding D-K, Zhang N, Wang J-X, Yang H-Y, Zhang D. MicroRNA-211 causes ganglion cell dysplasia in congenital intestinal atresia via down-regulation of glial-derived neurotrophic factor. *Neurogastroenterol Motil* 2016; 28: 186–195.
- Xie F, Li BX, Kassenbrock A, Xue C, Wang X, Qian DZ, et al. Identification of a potent inhibitor of CREB-mediated gene transcription with efficacious in vivo anticancer activity. *J Med Chem* 2015; 58: 5075–5087.
- Xu Q, Cobos I, De La Cruz ED, Rubenstein JL, Anderson SA. Origins of cortical interneuron subtypes. *J Neurosci* 2004; 24: 2612–2622.
- Zaman V, Li Z, Middaugh L, Ramamoorthy S, Rohrer B, Nelson ME, et al. The noradrenergic system of aged GDNF heterozygous mice. *Cell Transplant* 2003; 12: 291–303.
- Zeisel A, Muñoz-Manchado AB, Codeluppi S, Lönnerberg P, La Manno G, Jureus A, et al. Cell types in the mouse cortex and hippocampus revealed by single-cell RNA-seq. *Science* (80-) 2015; 347: 1138–1142.
- Zhang L, Deng J, Pan Q, Zhan Y, Fan J-B, Zhang K, et al. Targeted methylation sequencing reveals dysregulated Wnt signaling in Parkinson disease. *J Genet Genomics* 2016; 43: 587–92.
- Zhang H, Chang Y, Zhang L, Kim S-N, Otaegi G, Zhang Z, et al. Upregulation of microRNA miR-9 is associated with microcephaly and Zika virus infection in mice. *Mol Neurobiol* 2019; 56: 4072–4085.
- Zhao Y, Marin O, Hermes E, Powell A, Flames N, Palkovits M, et al. The LIM-homeobox gene *Lhx8* is required for the development of many cholinergic neurons in the mouse forebrain. *Proc Natl Acad Sci USA* 2003; 100: 9005–9010.
- Zhou C, Yang G, Chen M, Wang C, He L, Xiang L, et al. *Lhx8* mediated Wnt and TGF $\beta$  pathways in tooth development and regeneration. *Biomaterials* 2015; 63: 35–46.